Literature DB >> 11864953

Liposomal amphotericin B and granulocyte colony-stimulating factor therapy in a murine model of invasive infection by Scedosporium prolificans.

Montserrat Ortoneda1, Javier Capilla, Isabel Pujol, F Javier Pastor, Emilio Mayayo, Joan Fernández-Ballart, Josep Guarro.   

Abstract

We established a reproducible lethal disseminated infection by the opportunistic fungus Scedosporium prolificans in an immunosuppressed murine model. We compared the effectiveness of the combined administration of liposomal amphotericin B (LAMB) and granulocyte colony-stimulating factor (G-CSF) with that of either agent alone and with that of amphotericin B deoxycholate (AMB). LAMB + G-CSF and LAMB treatments improved survival significantly with respect to the untreated control. The mean survival times of these three groups were 13.2, 9.1 and 7.9 days, respectively. Culture results in terms of colony counts for samples of deep organs were lower in mice treated with the combined therapy, although differences were not significant. Combined LAMB + G-CSF therapy could be a promising approach for the treatment of disseminated infections of S. prolificans, although further studies are required to determine the most appropriate doses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11864953     DOI: 10.1093/jac/49.3.525

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

1.  Treatment options in emerging mold infections.

Authors:  Patricia Muñoz; Jesús Guinea; Emilio Bouza
Journal:  Curr Infect Dis Rep       Date:  2008-11       Impact factor: 3.725

2.  In vitro synergistic interaction between amphotericin B and micafungin against Scedosporium spp.

Authors:  Clara Yustes; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Activities of flucytosine, fluconazole, amphotericin B, and micafungin in a murine model of disseminated infection by Candida glabrata.

Authors:  Marçal Mariné; Carolina Serena; Belkys Fernández-Torres; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

Review 4.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

Review 5.  Melanized fungi in human disease.

Authors:  Sanjay G Revankar; Deanna A Sutton
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

6.  Comparative Pathogenicity of Lomentospora prolificans (Scedosporium prolificans) Isolates from Mexican Patients.

Authors:  Mariana Elizondo-Zertuche; Alexandra M Montoya; Efrén Robledo-Leal; Idalia Garza-Veloz; Ana L Sánchez-Núñez; Raquel Ballesteros-Elizondo; Gloria M González
Journal:  Mycopathologia       Date:  2017-04-29       Impact factor: 2.574

Review 7.  Host immune response against Scedosporium species.

Authors:  Emmanuel Roilides; Maria Simitsopoulou; Aspasia Katragkou; Thomas J Walsh
Journal:  Med Mycol       Date:  2009-01-31       Impact factor: 4.076

8.  Effects of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans.

Authors:  M Mar Rodríguez; Enrique Calvo; Carolina Serena; Marçal Mariné; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

9.  Efficacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolificans infection in rabbits.

Authors:  Javier Capilla; Clara Yustes; Emili Mayayo; Belkys Fernández; Montserrat Ortoneda; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

10.  Efficacy of liposomal amphotericin B in treatment of systemic murine fusariosis.

Authors:  Montserrat Ortoneda; Javier Capilla; Francisco J Pastor; Isabel Pujol; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.